Next Science Limited (NXSCF)

Market Cap	11.46M
Revenue (ttm)	22.82M
Net Income (ttm)	-10.59M
Shares Out	n/a
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,100
Average Volume	3,771
Open	0.0515
Previous Close	0.0050
Day's Range	0.0052 - 0.0515
52-Week Range	0.0052 - 0.1967
Beta	1.31
RSI	37.30
Earnings Date	Jul 25, 2025

About Next Science

Next Science Limited engages in the research, development, and commercialization of technologies that resolve the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial wound Gel; acne gel; oral rinse; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides wound management by maintaining a moist wound environment, which is conducive to wound healing; and XPERIENCE for use in cleansing and removal of debris, i...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2012
• Country: Australia
• Stock Exchange: OTCMKTS
• Ticker Symbol: NXSCF

Financial Performance

In 2024, Next Science's revenue was $22.82 million, an increase of 2.87% compared to the previous year's $22.18 million. Losses were -$10.59 million, -34.94% less than in 2023.